Tarjeta postal enviada por José M. Barrenetxea a Justo Garate en 1971

1 tarjeta postal (manuscrita) ; 150x100mmm

Cartas enviadas por José Mª Barriola a Justo Garate entre 1958 y 1965

2 cartas (manuscritas) ; entre 210x210mm y 210x160mm

Cartas enviadas por Charles Becker y por su viuda (M. L. Becker) entre 1929 y 1942

1 tarjeta postal y 1 carta (manuscritas) ; entre 140x90mm y 215x275mm

Cartas enviadas por José Belbey a Justo Garate entre 1954 y 1956

2 cartas (manuscritas) ; 135x220mm

Cartas enviadas por José María Bengoa a Justo Garate entre 1947 y 1961

11 cartas (mecanografiadas y manuscritas); entre 170x225mm y 215x275mm

Cartas enviadas por José María Bengoa a Justo Garate entre 1962 y 1992

8 cartas (mecanografiadas y manuscritas); entre 150x210mm y 215x275mm .- 1 Felicitación de Navidad (manuscrita y sin fecha) ; 110mmx160mm

Francesc Gusi i Jener (1942-2012): in memoriam

Homenaje a Georges Laplace, realizado en Vitoria-Gasteiz el 13,14 y 15 de noviembre de 2012. Edición a cargo de Aitor Calvo, Aitor Sánchez, Maite García-Rojas y Mónica Alonso-Eguíluz.

Carta enviada por José Berruezo a Justo Garate en 1973

1 carta (mecanografiada) ; 215x300mm

Lymphangioleiomyomatosis Biomarkers Linked to Lung Metastatic Potential and Cell Stemness

Lymphangioleiomyomatosis (LAM) is a rare lung-metastasizing neoplasm caused by the proliferation of smooth muscle-like cells that commonly carry loss-of-function mutations in either the tuberous sclerosis complex 1 or 2 (TSC1 or TSC2) genes. While allosteric inhibition of the mechanistic target of rapamycin (mTOR) has shown substantial clinical benefit, complementary therapies are required to improve response and/or to treat specific patients. However, there is a lack of LAM biomarkers that could potentially be used to monitor the disease and to develop other targeted therapies. We hypothesized that the mediators of cancer metastasis to lung, particularly in breast cancer, also play a relevant role in LAM. Analyses across independent breast cancer datasets revealed associations between low TSC1/2 expression, altered mTOR complex 1 (mTORC1) pathway signaling, and metastasis to lung. Subsequently, immunohistochemical analyses of 23 LAM lesions revealed positivity in all cases for the lung metastasis mediators fascin 1 (FSCN1) and inhibitor of DNA binding 1 (ID1). Moreover, assessment of breast cancer stem or luminal progenitor cell biomarkers showed positivity in most LAM tissue for the aldehyde dehydrogenase 1 (ALDH1), integrin-beta 3 (ITGB3/CD61), and/or the sex-determining region Y-box 9 (SOX9) proteins. The immunohistochemical analyses also provided evidence of heterogeneity between and within LAM cases. The analysis of Tsc2-deficient cells revealed relative over-expression of FSCN1 and ID1; however, Tsc2-deficient cells did not show higher sensitivity to ID1-based cancer inhibitors. Collectively, the results of this study reveal novel LAM biomarkers linked to breast cancer metastasis to lung and to cell stemness, which in turn might guide the assessment of additional or complementary therapeutic opportunities for LAM.